KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
Naomi Nakayama(Shimane University), Kaoru Miyazaki(Yokohama City University)
Cited by 114
Related Papers
EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
|British Journal of Cancer|2011|77
Binding of Active Matrilysin to Cell Surface Cholesterol Sulfate Is Essential for Its Membrane-associated Proteolytic Action and Induction of Homotypic Cell Adhesion
|Journal of Biological Chemistry|2006|45
Amino‐terminal fragments of laminin γ2 chain retract vascular endothelial cells and increase vascular permeability
|Cancer Science|2013|14
NAC1 Regulates PCK2 Expression and Activates Truncated Gluconeogenesis for Growth Advantage in Ovarian Cancer Cells
|International Journal of Molecular Sciences|2025|1